Amsterdam and Bethesda, January 16, 2018 - IOS Press, an international scientific, technical and medical publisher, and the Bladder Cancer Advocacy Network (BCAN), are pleased to announce that the journal Bladder Cancer is now the official journal of BCAN.
As the result of this new partnership, Bladder Cancer and BCAN will combine resources to support a readily accessible information platform to serve the bladder cancer research and clinical practice communities. As such, the journal is dedicated to providing an open forum for publishing original peer-reviewed research in basic science, translational research and clinical medicine that will improve the fundamental understanding of bladder cancer and lead to more effective treatment of tumors of the bladder and upper urinary tract and improved patient outcomes.
"We are very excited by our new partnership with BCAN, which will enable us to further enhance Bladder Cancer's reputation, share significant scientific advancements with a wider global audience, expand the journal's communities of readers and contributors, and support important advocacy efforts," commented Editors-in-Chief Seth P. Lerner, MD, Baylor College of Medicine, and Dan Theodorescu, MD, PhD, University of Colorado Cancer Center.
Launched in 2015, Bladder Cancer is an international multidisciplinary journal designed to facilitate progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pharmacology, ethics, patient advocacy and survivorship, diagnosis and treatment of tumors of the bladder and upper urinary tract. Guided by an eminent editorial board comprised of global leaders in the field, the journal publishes research reports, reviews, short communications, letters-to-the-editor, and special features that deliver timely commentary, alerts of groundbreaking research, clinical trials coverage, challenging case studies and access to current funding information.
Bladder cancer is the sixth most common cancer in the United States with over 81,000 new cases and nearly 17,000 deaths that were projected for 2017. With only recent advances in treatments over the past 30 years, there continues to be a tremendous need for more bladder cancer research. BCAN CEO Andrea Maddox-Smith notes, "Peer reviewed scientific journals like Bladder Cancer represent the most vital means for disseminating research findings to ultimately improve the lives and outcomes for bladder cancer patients. We enthusiastically look forward to the many scientific achievements that will be documented in this publication, and we are very excited to be able to announce Bladder Cancer as the official journal of the Bladder Cancer Advocacy Network."